Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04303039 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects
A Phase 1 study, sponsored by Atom Therapeutics Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04303039 is a Phase 1 study that has completed, run by Atom Therapeutics Co.. The registered enrollment target is 12 participants.
The verdict
NCT04303039, a Phase 1 study, has completed, sponsored by Atom Therapeutics Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a single center, open-label, single-dose, 2-way randomized crossover design in which 12 healthy subjects will be randomized to 1 of 2 treatment sequences (AB or BA). Treatments A and B will consist of single oral dose of tablet formulation (1.0 mg as 1 x 1.0 mg) in the fasted and fed state administered with approximately 240 mL of water. Each period will be separated by a washout interval of 4 days.
Interventions
- DRUG ABP-671
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-05-22 |
| Est. Completion | 2020-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04303039
The ClinicalTrials.gov registry entry for NCT04303039 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atom Therapeutics Co., which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABP-671 is the first listed.
NCT04303039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04303039 about?
NCT04303039 is a clinical study titled "Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects". This is a single center, open-label, single-dose, 2-way randomized crossover design in which 12 healthy subjects will be randomized to 1 of 2 treatment sequences (AB or BA). Treatments A and B will consist of single oral dose of tablet formulation (1.0 mg as 1 x 1.0 mg) in the fasted and fed state a...
What is the current status of trial NCT04303039?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-05-22. Estimated completion is 2020-06-19.
What interventions are being tested in trial NCT04303039?
The interventions under investigation include: ABP-671 (DRUG).
Who is sponsoring clinical trial NCT04303039?
This trial is sponsored by Atom Therapeutics Co., which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.